New! View global litigation for patent families

CA2398203A1 - Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations - Google Patents

Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Info

Publication number
CA2398203A1
CA2398203A1 CA 2398203 CA2398203A CA2398203A1 CA 2398203 A1 CA2398203 A1 CA 2398203A1 CA 2398203 CA2398203 CA 2398203 CA 2398203 A CA2398203 A CA 2398203A CA 2398203 A1 CA2398203 A1 CA 2398203A1
Authority
CA
Grant status
Application
Patent type
Prior art keywords
analyte
concentration
hematocrit
time
current
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2398203
Other languages
French (fr)
Inventor
Timothy J. Ohara
Mahyar Z. Kermani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lifescan Inc
Original Assignee
Lifescan, Inc.
Timothy J. Ohara
Mahyar Z. Kermani
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N27/00Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means
    • G01N27/26Investigating or analysing materials by the use of electric, electro-chemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
    • G01N27/28Electrolytic cell components
    • G01N27/30Electrodes, e.g. test electrodes; Half-cells
    • G01N27/327Biochemical electrodes electrical and mechanical details of in vitro measurements
    • G01N27/3271Amperometric enzyme electrodes for analytes in body fluids, e.g. glucose in blood
    • G01N27/3274Corrective measures, e.g. error detection, compensation for temperature or hematocrit, calibration

Abstract

Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied and a second time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration less a background value is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a function of the preliminary analyte concentration and the variable .gamma. of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.

Description

ELECTROCHEMICAL METHODS AND DEVICES FOR USE IN THE
DETERMINATION OF HEMATOCRIT CORRECTED ANALYTE
CONCENTRATIONS
INTRODUCTION
Field of the Invention The field of this invention is analyte determination, particularly electrochemical analyte determination and more particularly the electrochemical determination of blood analytes.
Background Analyte detection in physiological fluids, e.g. blood or blood derived products, is of ever increasing importance to today's society. Analyte detection assays find use in a variety of applications, including clinical laboratory testing, home testing, etc., where the results of such testing play a prominent role in diagnosis and management in a variety of disease conditions. Analytes of interest include glucose for diabetes management, cholesterol, and the like. In response to this growing importance of analyte detection, a variety of analyte detection protocols and devices for both clinical and home use have been developed.
One type of method that is employed for analyte detection is an electrochemical method. In such methods, an aqueous liquid sample is placed into a reaction zone in an electrochemical cell comprising two electrodes, i.e. a reference and working electrode, where the electrodes have an impedance which renders them suitable for amperometric measurement. The component to be analyzed is allowed to react directly with an electrode, or directly or indirectly with a redox reagent to form an oxidisable (or reducible) substance in an amount corresponding to the concentration of the component to be analyzed, i.e.
analyte. The quantity of the oxidisable (or reducible) substance present is then estimated electrochemically and related to the amount of analyte present in the initial sample.
Where the physiological sample being assayed is whole blood or a derivative thereof, the hematocrit of the sample can be a source of analytical error in the ultimate analyte concentration measurement. For example, in electrochemical measurement protocols where 3o the analyte concentration is derived from observed time-current transients, hematocrit can slow the equilibration chemistry in the electrochemical cell and/or slow the enzyme kinetics by increasing the sample viscosity in the cell, thereby attenuating the time current response and causing analytical error.

As such, there is great interest in the development of methods of at least minimizing the hematocrit originated analytical error. In certain protocols, blood filtering membranes are employed to remove red blood cells and thereby minimize the hematocrit effect.
These particular protocols are unsatisfactory in that increased sample volumes and testing times are required. Other protocols focus on the determination of the capillary fill time. However, these protocols add complexity to both the strips and devices that are used to read them. In yet other embodiments, hematocrit is separately determined using two additional electrodes, which also results in more complex and expensive strips/devices.
As such, there is continued interest in the identification of new methods for 1o electrochemically measuring the concentration of an analyte in a physiological sample, where the method minimizes the analytical error which originates with the hematocrit of the sample.
Relevant Literature Patent documents of interest include: 5,942,102 and WO 97/18465.
SUMMARY OF THE INVENTION
Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first 2o electric potential is applied to the cell and the resultant cell current over a first period of time is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied to the cell and a second time-current transient is determined.
The preliminary concentration of the analyte (Co)is then calculated from the first and/or second time-current transients. This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a fiznction of the preliminary analyte concentration and the ratio of 2 current values (y) within the time-current transient of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for the 3o determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose.

BRIEF DESCRIPTION OF THE FIGURES
Fig. 1 provides a three-dimensional graph of Co, y and a.(Co, y) derived from experimental data using a wide range of glucose and hematocrit values.
DESCRIPTION OF THE SPECIFIC EMBODIMENTS
Methods and devices for determining the concentration of an analyte in a physiological sample are provided. In the subject methods, the physiological sample is introduced into an electrochemical cell having a working and reference electrode. A first electric potential is applied to the cell and the resultant cell current over a first period of time 1o is measured to determine a first time-current transient. A second electric potential of opposite polarity is then applied to the cell and a second a time-current transient is determined. The preliminary concentration of the analyte is then calculated from the first and/or second time-current transient. This preliminary analyte concentration, less a background value, is then multiplied by a hematocrit correction factor to obtain the analyte concentration in the sample, where the hematocrit correction factor is a fiznction of the preliminary analyte concentration and the variable y of the electrochemical cell. The subject methods and devices are suited for use in the determination of a wide variety of analytes in a wide variety of samples, and are particularly suited for use in the determination of analytes in whole blood or derivatives thereof, where an analyte of particular interest is glucose. In 2o fizrther describing the subject invention, the subject methods will be described first followed by a review of a representative device for use in practicing the subject methods.
Before the subject invention is described fi~rther, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting.
Instead, the scope of the present invention will be established by the appended claims.
3o In this specification and the appended claims, singular references include the plural, unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

METHODS
As summarized above, the subject invention provides a method for determining a hematocrit corrected analyte concentration value in a physiological sample. By hematocrit corrected analyte concentration is meant that the analyte concentration value determined using the subject methods has been modulated or changed to remove substantially all contribution of hematocrit to the value. In other words, the concentration value that is determined using the subject methods has been modified so that any contribution to the value from the hematocrit of the sample that would be present in the value but for the 1o practicing of the subject methods is removed. As such, the hematocrit signal is deconvoluted from the analyte signal in the subject methods, and only the analyte signal is employed in arriving at the final hematocrit corrected analyte concentration.
The first step in the subject methods is to introduce a quantity of the physiological sample of interest into an electrochemical cell that includes spaced apart working and reference electrodes and a redox reagent system. The physiological sample may vary, but in many embodiments is generally whole blood or a derivative or fraction thereof, where whole blood is of particular interest in many embodiments. The amount of physiological sample, e.g. blood, that is introduced into the reaction area of the test strip varies, but generally ranges from about 0.1 to 10 p.L, usually from about 0.9 to 1.6 p,L. The sample is introduced 2o into the reaction area using any convenient protocol, where the sample may be injected into the reaction area, allowed to wick into the reaction area, and the like, as may be convenient.
While the subject methods may be used, in principle, with any type of electrochemical cell having spaced apart working and reference electrodes and a redox reagent system, in many embodiments the subject methods employ an electrochemical test strip. The electrochemical test strips employed in these embodiments of the subject invention are made up of two opposing metal electrodes separated by a thin spacer layer, where these components define a reaction area or zone in which is located a redox reagent system.
In certain embodiments of these electrochemical test strips, the working and reference electrodes are generally configured in the form of elongated rectangular strips.
3o Typically, the length of the electrodes ranges from about 1.9 to 4.5 cm, usually from about 2.0 to 2.8 cm. The width of the electrodes ranges from about 0.38 to 0.76 cm, usually from about 0.51 to 0.67 cm. The reference electrodes typically have a thickness ranging from about 10 to 100 nm and usually from about 10 to 20 nm. In certain embodiments, the length of one of the electrodes is shorter than the length of the other electrode, typically about 0.32 cm. The shorter electrode may be the working or reference electrode.
The working and reference electrodes are further characterized in that at least the surface of the electrodes that faces the reaction area in the strip is a metal, where metals of interest include palladium, gold, platinum, silver, iridium, carbon, doped tin oxide, stainless steel and the like. In many embodiments, the metal is gold or palladium. While in principle the entire electrode may be made of the metal, each of the electrodes is generally made up of an inert support material on the surface of which is present a thin layer of the metal component of the electrode. In these more common embodiments, the thickness of the inert 1o backing material typically ranges from about 51 to 356 Vim, usually from about 102 to 153 ~m while the thickness of the metal layer typically ranges from about 10 to 100 nm and usually from about 10 to 40 nm, e.g. a sputtered metal layer. Any convenient inert backing material may be employed in the subject electrodes, where typically the material is a rigid material that is capable of providing structural support to the electrode and, in turn, the electrochemical test strip as a whole. Suitable materials that may be employed as the backing substrate include plastics, e.g. PET, PETG, polyimide, polycarbonate, polystyrene, silicon, ceramic, glass, and the like.
A feature of the electrochemical test strips used in these embodiments of the subject methods is that the working and reference electrodes as described above face each other and 2o are separated by only a short distance, such that the distance between the working and reference electrode in the reaction zone or area of the electrochemical test strip is extremely small. This minimal spacing of the working and reference electrodes in the subject test strips is a result of the presence of a thin spacer layer positioned or sandwiched between the working and reference electrodes. The thickness of this spacer layer generally should be less than or equal to 500 Vim, and usually ranges from about 102 to 153 Vim. The spacer layer is cut so as to provide a reaction zone or area with at least an inlet port into the reaction zone, and generally an outlet port out of the reaction zone as well. The spacer layer may have a circular reaction area cut with side inlet and outlet vents or ports, or other configurations, e.g. square, triangular, rectangular, irregular shaped reaction areas, etc.
The spacer layer may 3o be fabricated from any convenient material, where representative suitable materials include PET, PETG, polyimide, polycarbonate, and the like, where the surfaces of the spacer layer may be treated so as to be adhesive with respect to their respective electrodes and thereby maintain the structure of the electrochemical test strip. Of particular interest is the use of a die-cut double-sided adhesive strip as the spacer layer.
The electrochemical test strips used in these embodiments of the subject invention include a reaction zone or area that is defined by the working electrode, the reference electrode and the spacer layer, where these elements are described above.
Specifically, the working and reference electrodes define the top and bottom of the reaction area, while the spacer layer defines the walls of the reaction area. The volume of the reaction area is at least about 0.1 pL, usually at least about 1 ~L and more usually at least about 1.5 ~L, where the volume may be as large as 10 p.L or larger. As mentioned above, the reaction area generally 1o includes at least an inlet port, and in many embodiments also includes an outlet port. The cross-sectional area of the inlet and outlet ports may vary as long as it is sui~ciently large to provide an effective entrance or exit of fluid from the reaction area, but generally ranges from about 9 x 10~ to 5 x 10-3 cm2, usually from about 1.3 x 10-3 to 2.5 x 10-3 cm2.
Present in the reaction area is a redox reagent system, which reagent system provides for the species that is measured by the electrode and therefore is used to derive the concentration of analyte in a physiological sample. The redox reagent system present in the reaction area typically includes at least an enzymes) and a mediator. In many embodiments, the enzyme members) of the redox reagent system is an enzyme or plurality of enzymes that work in concert to oxidize the analyte of interest. In other words, the enzyme component of the redox reagent system is made up of a single analyte oxidizing enzyme or a collection of two or more enzymes that work in concert to oxidize the analyte of interest.
Enzymes of interest include oxidases, dehydrogenases, lipases, kinases, diphorases, quinoproteins, and the like.
The specific enzyme present in the reaction area depends on the particular analyte for which the electrochemical test strip is designed to detect, where representative enzymes include: glucose oxidase, glucose dehydrogenase, cholesterol esterase, cholesterol oxidase, lipoprotein lipase, glycerol kinase, glycerol-3-phosphate oxidase, lactate oxidase, lactate dehydrogenase, pyruvate oxidase, alcohol oxidase, bilirubin oxidase, uricase, and the like. In many preferred embodiments where the analyte of interest is glucose, the enzyme 3o component of the redox reagent system is a glucose oxidizing enzyme, e.g. a glucose oxidase or glucose dehydrogenase.
The second component of the redox reagent system is a mediator component, which is made up of one or more mediator agents. A variety of different mediator agents are known in the an and include: ferricyanide, phenazine ethosulphate, phenazine methosulfate, pheylenediamine, 1-methoxy-phenazine methosulfate, 2,6-dimethyl-1,4-benzoquinone, 2,5-dichloro-1,4-benzoquinone, ferrocene derivatives, osmium bipyridyl complexes, ruthenium complexes, and the like. In those embodiments where glucose in the analyte of interest and glucose oxidase or glucose dehydrogenase are the enzyme components, mediators of particular interest are ferricyanide, and the like.
Other reagents that may be present in the reaction area include buffering agents, e.g.
citraconate, citrate, malic, malefic, phosphate, "Good" buffers and the like.
Yet other agents that may be present include: divalent canons such as calcium chloride, and magnesium to chloride; pyrroloquinoline quinone; types of surfactants such as Triton, Macol, Tetronic, Silwet, Zonyl, and Pluronic; stabilizing agents such as albumin, sucrose, trehalose, mannitol, and lactose.
The redox reagent system is generally present in dry form. The amounts of the various components may vary, where the amount of enzyme component typically ranges from about 1 to 100 mg/mL, usually from about 5 to 80mg/mL; and the amount of mediator component typically ranges from about 5 to 1000 mM, usually from about 90 to 900 mM.
Following sample introduction, first and second time-current transients are obtained.
The first and second time-current transients are obtained by applying a constant electric potential to the cell and observing the change in current over a period of time in the cell. In other words, first and second pulses are applied to the cell and the resultant time-current transients are observed. As such, the first time-current transient is obtained by applying a constant electric potential or first pulse to the cell, e.g. between the working and the reference electrodes, and observing the change in current over time between the electrodes, i.e. change in cell current, to obtain the first time-current transient. The magnitude of the first applied electric potential generally ranges from about 0 to -0.6 V, usually from about -0.2 to -0.4 V. The length of time over which the current between the electrodes is observed to obtain the first time-current transient typically ranges from about 3 to 20 seconds, usually from about 4 to 10 seconds.
The second time current is obtained by applying a second constant electric potential or second pulse, typically of opposite polarity from the first constant electric potential, to the electrodes and observing the change in current between the electrodes for a second period of time. The magnitude of this second constant electric potential typically ranges from about 0 to +0.6 V, usually from about +0.2 to +0.4 V, where in many embodiments the magnitude of the second electric potential is the same as the magnitude of the first electric potential.
The second time period typically ranges from about 1 to 10 seconds, usually from about 2 to 4 seconds. By observing the change in current between the electrodes over this second period of time, a second time-current transient for the cell is determined.
The overall time period required to obtain the requisite first and second time-current transients, as described above, is relatively short in certain embodiments. In such embodiments, the total amount of time required to obtain the first and second time-current transients is less than about 30 seconds, usually less than about 20 seconds and more usually less than about 14 seconds.
to The next step in the subject methods is to use the observed first and second time-current transients, obtained as described above, to determine: (a) the variable y of the electrochemical cell used in the subject methods; and (b) a preliminary analyte concentration for the analyte of interest in the sample.
The variable ~r employed in the subject methods is defined to describe the deviation of the electrochemical cell from ideality. By way of background, it should be noted that y should approach unity under ideal conditions, i.e. reagent equilibration and glucose reaction are complete before the end of the first pulse. Any of these conditions not being complete will cause the ratio to deviate fron non-unity values. The numerator of y is defined as the steady-state current observed following application of the second electric potential to 2o the cell, i.e. predicted value at t=oc of the second time-current transient. The denominator is defined as the average current over a short time period near the end of the first period of time, i.e. near the end of the application of the first electric potential or first pulse. The short period of time from which the average current is determined typically ranges from .2 to 2 seconds, usually from about .2 to 1.5 seconds and more usually from about .2 to 1.25 seconds, where in many embodiments the short period of time is about .3 second. The average current is determined at a time near the end of the first time period, typically within about 0.1 to 1 second,. In certain embodiments, the variable y is described by the formula:
155~1PP
where:
iss is the steady-state current of the second applied electric potential; and iPP is the average current over a short period of time near the end of first time period, i.e. near the end of the time during which the first electric potential is applied to the cell. For example, where the first time period is 10 seconds long, the average current may be the s average current from 8.5 to 9.5 seconds of the 10 second long period, which is a 1.0 second time period 0.5 seconds from the end of the first time period As mentioned above, the first and second time-current transients are also employed to derive a preliminary analyte concentration value for the sample being assayed. In many embodiments, the preliminary analyte concentration is determined by using the following equations:
i(t) = iss { 1 + 4 exp(-4~t2Dt/L2) }
iss = 2 FADCo/L
where iss is the steady-state current following application of the second electric potential;
1o i is the measured current which is a function of time D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, i.e. J(x,t)=-Ddc~~,t~/dX
L is the spacer thickness;
t is the time for the application of the 2"d electric potential where t=0 for the beginning of the pulse Co is the preliminary concentration of the analyte;
F is faraday's constant, i.e. 9.6485x104C/mol; and A is the area of the working electrode.
2o Using the above equations and steps, the observed first and second time-current transients are used to determine the variable y of the electrochemical cell employed in the subject method and the preliminary concentration value of the analyte of interest in the assayed physiological sample.
From the determined variable y and preliminary analyte concentration value, a hematocrit correction factor is determined, which hematocrit correction factor is used to obtain a hematocrit corrected analyte concentration value from the initial or preliminary analyte concentration value described above. The hematocrit correction factor is a factor with which the preliminary analvte concentration (typically less a background value) may be multiplied in order to obtain a hematocrit corrected analyte concentration value, i.e. a 3o concentration value from which the hematocrit component has been removed.
The hematocrit correction factor is a function of both the preliminary analyte concentration value and the variable 'y of the electrochemical cell.

Any hematocrit correction factor that can be multiplied by the preliminary concentration value (usually less a background value, as described in greater detail below) may be employed in the subject methods. One class of hematocrit correction factors that find use in the subject methods are those that are derived from a three dimensional graph of Co, y and oc(Co, ~r) obtained from experimental data using a wide range of analyte and hematocrit values. The hematocrit correction factor (a(Co, Y)) is determined using the formula:
a(Co, ~/) =actual concentration/( Co -Background Value) (For example, where the analyte is glucose, a(Co, y) in many embodiments equals the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer to model 23A (as described in U.S. Patent No. 5, 968,760 the disclosure of which is herein incorporated by reference) divided by the Co less a background value, e.g. 22 mg/dL). This class of hematocrit correction factors are typically equations which fit a smooth surface function that minimizes the error between the predicted and actual data. See e.g. the experimental section, infra. One representative hematocrit correction factor that finds use in the subject methods is:
1/((0.6637) + ((4.9466*ln(Ca))/ Co) + (-0.4012*ln(y))) In determining the hematocrit corrected concentration of analyte according to the subject invention, the preliminary analyte concentration (Co) as determined above, less a background signal value, is multiplied by the hematocrit correction factor.
The background value that is subtracted from the preliminary concentration value depends on the analyte being measured. For glucose, this value typically ranges from about 0 to 40 mg/dL, usually from about 8 to 25 mg/dL, where in many embodiments the background value is about 22 mg/dL or is 22 mg/dL.
Generally, the following formula is employed to determine the hematocrit corrected analyte concentration according to the subject invention:
hematocrit corrected concentration = hematocrit correction factor x[ Co - (3]
where (3 is the background value; and Co is the preliminary analyte concentration.
The above described methods yield a hematocrit corrected analyte concentration value, i.e. a concentration value in which the hematocrit component has been deconvoluted and removed. As such, the above described methods provide for an accurate value of the concentration of the analyte in the sample being assayed.
The above computational steps of the subject method may be accomplished manually or through the use of an automated computing means, where in many embodiments the use of an automated computing means, such as is described in connection with the subject devices discussed below, is of interest.
DEVICES
Also provided by the subject invention are meters for use in practicing the subject to invention. The subject meters are typically meters for amperometrically measuring the hematocrit corrected concentration of an analyte in a physiological sample.
The subject meters typically include: (a) a means for applying a first electric potential to an electrochemical cell into which the sample has been introduced and measuring cell current as a function of time to obtain a first time-current transient; (b) a means for applying a second 15 electric potential to the electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient; (c) a means for determining a preliminary analyte concentration value and a variable y from said first and second time-currents;
and (d) a means for removing the hematocrit component from the preliminary concentration value to derive the hematocrit corrected analyte concentration in said sample. Means (a) and (b) may 2o be any suitable means, where representative means are described in WO
97/18465 and U.S.
Patent No. 5,942,102; the disclosures of which are herein incorporated by reference. Means (c) and (d) are typically computing means present in the meter which are capable of using the measured first and second time current transients to ultimately obtain the hematocrit corrected analyte concentration. As such, means (c) is typically a means that is capable of 25 determining the preliminary concentration of the analyte of interest and the variable y from the first and second time-current transients using the equations described above. Likewise, means (d) is typically a means that is capable of determining the hematocrit corrected analyte concentration using the equations described above, where this means typically comprises the hematocrit correction factor.
The following examples are offered by way of illustration and not by way of limitation.

EXPERIMENTAL
I. Electrochemical Test Strip Preparation An electrochemical test strip consisting of two metallized electrodes oriented in a sandwich configuration was prepared as follows. The top layer of the test strip was a gold sputtered Mylar strip. The middle layer was a double-sided adhesive with a punched hole that defined the reaction zone or area. The punched hole was a circle with two juxtaposed rectangular inlet and outlet channels. The bottom layer of the test strip was sputtered palladium on Mylar. A film of ferricyanide and glucose dehydrogenase PQQ was deposited on the palladium sputtered surface.
II. Generation of Experimental Data First and second time current transients for a number of different samples varying by glucose concentration and hematocrit were obtained as follows. Sample was applied to the strip which actuated an applied potential of -.03 V for a period of 10 seconds which was then followed by a second pulse of +0.3 V for a period of 3 to 10 seconds (where these electrode potentials are with respect to the gold electrode).
III. Derivation of Hematocrit Correction Factor for Glucose For a wide range of glucose and hematocrit values measured as described above, Co, 2o the variable y and a,(Co, ~r) were derived.
Co was derived using the equations:
i(t) = iss { 1 + 4 exp(-4~ZDt/LZ) ~
iSS = 2 FADCo/L
where iss is the steady-state current following application of the second electric potential;
i is the measured current which is a function of time D is the diffusion coefficient of the cell, where this coefficient may be determined from Fick's first law, i.e. J(x,t)=-D dC(~t)/ax L is the spacer thickness;
3o t is the time for the application of the 2"d electric potential where t=0 for the beginning of the pulse;
Co is the preliminary concentration of the analyte;
F is faraday's constant, i. e. 9.6485 x 104C/mol; and A is the area of the electrode surface.
The variable y was derived using the equation:
lss / 1PP
where:
iss is the steady-state current of the second applied electric potential or second pulse;
and iPP is the average current from 8.5 to 9.5 seconds of the 10 s long period during which the first pulse was applied.
to oc(Co, y) was determined using the equation:
oc(Co, y) =YSI concentration/( C° -22 mg/dL) where YSI is the glucose concentration as determined using the Yellow Springs Instrument glucose analyzer model 23A (as described in U.S. Patent No. 5, 968,760 the disclosure of which is herein incorporated by reference).
A three-dimensional graph of Co, y and oc(Co, y) as determined above for a wide range of glucose and hematocrit values was prepared and is shown in Fig. 1. A
simple equation fit was then performed on the graph to define the surface. The residual of the fitted data was monitored to ascertain the quality of the model equation. The empirical equation 2o was found to be:
Hematocrit Correction Factor = 1/((0.6637) + ((4.9466*ln(C°))/ Co) + (-0.4012*ln(y))) The above correction factor was found to be valid for those situations where the y >0.7 and Ca >40 mg/dL.
IV. Comparison of Hematocrit Corrected Values to YSI determined Values.
A prediction data set was generated by testing several glucose strips with a wide range of glucose and hematocrit levels. From this data a hematocrit correction equation was derived using a model which fits the terms Co, y, and oc(C°, y) . It was found that using the hematocrit correction equation on the prediction data set causes the majority of data points to 3o fall within +/- 15%. It was also found that the bias of the glucose results to 42% hematocrit, indicating that the hematocrit effect on this data set is minimal. In order to confirm this algorithm, another batch of glucose sesnsors was tested with a different blood donor. It was found that the algorithm still corrects for the hematocrit effect in a manner analogous to the earlier findings.
The above results and discussion demonstrate that subject invention provides a simple and powerful tool to obtain analyte concentration values in which hematocrit derived error is substantially if not entirely eliminated. As the subject methods rely solely on the measurement of time-current transients, they may be practiced with relatively simple electrochemical devices. Furthermore, only small sample volumes need be employed and relatively quick assay times are provided. As such, the subject invention represents a to significant contribution to the art.
All publications and patents cited in this specification are herein incorporated by reference as if each individual publication or patent were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure 15 prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to 2o those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
1~

Claims (20)

1. A method for determining the hematocrit corrected concentration of an analyte in a physiological sample, said method comprising:
(a) introducing said physiological sample into an electrochemical cell comprising:
(i) spaced apart working and reference electrodes; and (ii) a redox reagent system comprising an enzyme and a mediator;
(b) applying a first electric potential to said reaction cell and measuring cell current as a function of time to obtain a first time-current transient;
(c) applying a second electric potential to said cell and measuring cell current as a function of time to obtain a second time-current transient; and (d) deriving a preliminary analyte concentration from said first and second time-current transients; and (e) multiplying said preliminary analyte concentration less a background value by a hematocrit correction factor to derive said hematocrit corrected analyte concentration in said sample;
whereby the hematocrit corrected concentration of said analyte in said sample is determined.
2. The method according to Claim 1, wherein said hematocrit correction factor modulates the preliminary analyte concentration value to remove the hematocrit derived component of said preliminary analyte concentration value.
3. The method according to Claim 1, wherein said hematocrit correction factor is a function of said preliminary analyte concentration and .gamma. of said electrochemical cell.
4. The method according to Claim 1, wherein said physiological sample is whole blood or a derivative thereof.
5. The method according to Claim 1, wherein said analyte is glucose.
6. A method for determining the hematocrit corrected concentration of an analyte in a whole blood sample, said method comprising:
(a) introducing said whole blood sample into an electrochemical cell comprising:
(i) spaced apart working and reference electrodes; and (ii) a redox reagent system comprising an enzyme and a mediator;
(b) applying a first electric potential to said reaction cell and measuring cell current as a function of time to obtain a first time-current transient;
(c) applying a second electric potential to said cell and measuring cell current as a function of time to obtain a second time-current transient; and (d) deriving a preliminary analyte concentration value from said first and second time-current transients; and (e) multiplying said preliminary analyte concentration less a background value by a hematocrit correction factor that removes the hematocrit component from said preliminary concentration value to derive said hematocrit corrected analyte concentration in said sample;
whereby the hematocrit corrected concentration of said analyte in said sample is determined.
7. The method according to Claim 6, wherein said hematocrit correcting factor is a function of said preliminary analyte concentration and a variable .gamma. of said electrochemical cell.
8. The method according to Claim 6, wherein said analyte is glucose.
9. The method according to Claim 6, wherein said enzyme is an oxidizing enzyme.
10. The method according to Claim 9, wherein said oxidizing enzyme is a glucose oxidizing enzyme.
11. A method for determining the hematocrit corrected concentration of glucose in a whole blood sample, said method comprising:
(a) introducing said whole blood sample into an electrochemical cell comprising:
(i) spaced apart working and reference electrodes; and (ii) a redox reagent system comprising a glucose oxidizing enzyme and a mediator;
(b) applying a first electric potential to said reaction cell and measuring cell current as a function of time to obtain a first time-current transient;
(c) applying a second electric potential to said cell and measuring cell current as a function of time to obtain a second time-current transient; and (d) deriving a preliminary glucose concentration value from said first and second time-current transients; and (e) multiplying said preliminary glucose concentration value less a background value by a hematocrit correction factor that removes the hematocrit component from said preliminary concentration value to derive said hematocrit corrected glucose concentration in said sample;
whereby the hematocrit corrected concentration of glucose in said sample is determined.
12. The method according to Claim 11, wherein said hematocrit correction factor is a function of said preliminary analyte concentration and a variable .gamma. of said electrochemical cell.
13. The method according to Claim 12, wherein said hematocrit correction factor equals:
1/((0.6637) + ((4.9466*1n(C o))/C o) + (-0.4012*1n(.gamma.))) wherein:
C o is said preliminary concentration; and .gamma. is said variable current ratio of said electrochemical cell.
14. The method according to Claim 13, wherein said preliminary glucose concentration of said sample is greater than 40 mg/dL.
15. The method according to Claim 13, wherein said variable .gamma. of said electrochemical cell is greater than 0.7.
16. A meter for amperometrically measuring the concentration of an analyte in a physiological sample, said meter comprising:
(a) means for applying a first electric potential to an electrochemical cell comprising said sample and measuring cell current as a function of time to obtain a first time-current transient;
(b) means for applying a second electric potential to said electrochemical cell and measuring cell current as a function of time to obtain a second time-current transient;
(c) means for determining a preliminary analyte concentration value and variable .gamma. from said first and second time-currents; and (d) means for removing the hematocrit component from said preliminary concentration value to derive said analyte concentration in said sample.
17. The meter according to Claim 16, wherein said means for removing the hematocrit component is a means for multiplying said preliminary analyte concentration value less a background value by a hematocrit correction factor.
18. The meter according to Claim 16, wherein said hematocrit correction factor is a function of said preliminary analyte concentration and said variable .gamma.
of said electrochemical cell.
19. The meter according to Claim 18, wherein said hematocrit correction factor equals:
1/((0.6637) + ((4.9466*1n(C o))/C o) + (-0.4012*1n(.gamma.))) wherein:
C o is said preliminary concentration; and .gamma. is said variable current ratio of said electrochemical cell.
20. The meter according to Claim 16, wherein said analyte is glucose.
CA 2398203 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations Abandoned CA2398203A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09497304 US6475372B1 (en) 2000-02-02 2000-02-02 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US09/497,304 2000-02-02
PCT/US2001/002465 WO2001057510A3 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Publications (1)

Publication Number Publication Date
CA2398203A1 true true CA2398203A1 (en) 2001-08-09

Family

ID=23976305

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2398203 Abandoned CA2398203A1 (en) 2000-02-02 2001-01-25 Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations

Country Status (10)

Country Link
US (3) US6475372B1 (en)
EP (2) EP1645876A3 (en)
JP (1) JP2003521708A (en)
CN (1) CN1193228C (en)
CA (1) CA2398203A1 (en)
DE (1) DE60116056T2 (en)
DK (1) DK1252514T3 (en)
ES (1) ES2254368T3 (en)
RU (2) RU2262890C2 (en)
WO (1) WO2001057510A3 (en)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036924A (en) 1997-12-04 2000-03-14 Hewlett-Packard Company Cassette of lancet cartridges for sampling blood
US8148164B2 (en) 2003-06-20 2012-04-03 Roche Diagnostics Operations, Inc. System and method for determining the concentration of an analyte in a sample fluid
US8071384B2 (en) 1997-12-22 2011-12-06 Roche Diagnostics Operations, Inc. Control and calibration solutions and methods for their use
US7494816B2 (en) * 1997-12-22 2009-02-24 Roche Diagnostic Operations, Inc. System and method for determining a temperature during analyte measurement
US6391005B1 (en) 1998-03-30 2002-05-21 Agilent Technologies, Inc. Apparatus and method for penetration with shaft having a sensor for sensing penetration depth
US6554798B1 (en) 1998-08-18 2003-04-29 Medtronic Minimed, Inc. External infusion device with remote programming, bolus estimator and/or vibration alarm capabilities
US20050103624A1 (en) 1999-10-04 2005-05-19 Bhullar Raghbir S. Biosensor and method of making
EP2275807B1 (en) * 1999-11-15 2014-04-23 Panasonic Healthcare Co., Ltd. Biosensor for quantifying a substrate
US6475372B1 (en) * 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
ES2312719T3 (en) * 2000-03-28 2009-03-01 Diabetes Diagnostics, Inc. Glucose meter with fast response sensor.
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor
US6591125B1 (en) * 2000-06-27 2003-07-08 Therasense, Inc. Small volume in vitro analyte sensor with diffusible or non-leachable redox mediator
US8641644B2 (en) 2000-11-21 2014-02-04 Sanofi-Aventis Deutschland Gmbh Blood testing apparatus having a rotatable cartridge with multiple lancing elements and testing means
EP2096435B1 (en) * 2000-11-30 2014-11-12 Panasonic Healthcare Co., Ltd. Method of quantifying substrate
US7892183B2 (en) 2002-04-19 2011-02-22 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
US8372016B2 (en) 2002-04-19 2013-02-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling and analyte sensing
US6855243B2 (en) 2001-04-27 2005-02-15 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers and methods for using the same
US9795334B2 (en) 2002-04-19 2017-10-24 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US8784335B2 (en) 2002-04-19 2014-07-22 Sanofi-Aventis Deutschland Gmbh Body fluid sampling device with a capacitive sensor
US7648468B2 (en) 2002-04-19 2010-01-19 Pelikon Technologies, Inc. Method and apparatus for penetrating tissue
US9226699B2 (en) 2002-04-19 2016-01-05 Sanofi-Aventis Deutschland Gmbh Body fluid sampling module with a continuous compression tissue interface surface
US7291117B2 (en) 2002-04-19 2007-11-06 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7981056B2 (en) 2002-04-19 2011-07-19 Pelikan Technologies, Inc. Methods and apparatus for lancet actuation
US8267870B2 (en) 2002-04-19 2012-09-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for body fluid sampling with hybrid actuation
US7717863B2 (en) 2002-04-19 2010-05-18 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7976476B2 (en) 2002-04-19 2011-07-12 Pelikan Technologies, Inc. Device and method for variable speed lancet
US8221334B2 (en) 2002-04-19 2012-07-17 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US7232451B2 (en) 2002-04-19 2007-06-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US8360992B2 (en) 2002-04-19 2013-01-29 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US9314194B2 (en) 2002-04-19 2016-04-19 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7901362B2 (en) 2002-04-19 2011-03-08 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9427532B2 (en) 2001-06-12 2016-08-30 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7371247B2 (en) 2002-04-19 2008-05-13 Pelikan Technologies, Inc Method and apparatus for penetrating tissue
WO2002100460A3 (en) 2001-06-12 2003-05-08 Don Alden Electric lancet actuator
US8337419B2 (en) 2002-04-19 2012-12-25 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US7491178B2 (en) 2002-04-19 2009-02-17 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7226461B2 (en) 2002-04-19 2007-06-05 Pelikan Technologies, Inc. Method and apparatus for a multi-use body fluid sampling device with sterility barrier release
US7331931B2 (en) 2002-04-19 2008-02-19 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7344507B2 (en) 2002-04-19 2008-03-18 Pelikan Technologies, Inc. Method and apparatus for lancet actuation
US7682318B2 (en) 2001-06-12 2010-03-23 Pelikan Technologies, Inc. Blood sampling apparatus and method
US7041068B2 (en) 2001-06-12 2006-05-09 Pelikan Technologies, Inc. Sampling module device and method
US7909778B2 (en) 2002-04-19 2011-03-22 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7297122B2 (en) 2002-04-19 2007-11-20 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7547287B2 (en) 2002-04-19 2009-06-16 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7674232B2 (en) 2002-04-19 2010-03-09 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US7229458B2 (en) 2002-04-19 2007-06-12 Pelikan Technologies, Inc. Method and apparatus for penetrating tissue
US9248267B2 (en) 2002-04-19 2016-02-02 Sanofi-Aventis Deustchland Gmbh Tissue penetration device
EP1404235A4 (en) 2001-06-12 2008-08-20 Pelikan Technologies Inc Method and apparatus for lancet launching device integrated onto a blood-sampling cartridge
US7316700B2 (en) 2001-06-12 2008-01-08 Pelikan Technologies, Inc. Self optimizing lancing device with adaptation means to temporal variations in cutaneous properties
US7699791B2 (en) 2001-06-12 2010-04-20 Pelikan Technologies, Inc. Method and apparatus for improving success rate of blood yield from a fingerstick
US8579831B2 (en) 2002-04-19 2013-11-12 Sanofi-Aventis Deutschland Gmbh Method and apparatus for penetrating tissue
US20030036202A1 (en) 2001-08-01 2003-02-20 Maria Teodorcyzk Methods and devices for use in analyte concentration determination assays
CN1304838C (en) * 2001-09-14 2007-03-14 爱科来株式会社 Concentration measuring method, concentration test instrument, and concentration measuring apparatus
USRE44522E1 (en) 2001-09-14 2013-10-08 Arkray, Inc. Concentration measuring method, concentration test instrument, and concentration measuring apparatus
USRE45764E1 (en) 2001-09-14 2015-10-20 Arkray, Inc. Concentration measuring method, concentration test instrument, and concentration measuring apparatus
US7018843B2 (en) * 2001-11-07 2006-03-28 Roche Diagnostics Operations, Inc. Instrument
US7276146B2 (en) * 2001-11-16 2007-10-02 Roche Diagnostics Operations, Inc. Electrodes, methods, apparatuses comprising micro-electrode arrays
US9017544B2 (en) 2002-10-04 2015-04-28 Roche Diagnostics Operations, Inc. Determining blood glucose in a small volume sample receiving cavity and in a short time period
US20030116447A1 (en) * 2001-11-16 2003-06-26 Surridge Nigel A. Electrodes, methods, apparatuses comprising micro-electrode arrays
US6872358B2 (en) 2002-01-16 2005-03-29 Lifescan, Inc. Test strip dispenser
US20030212379A1 (en) * 2002-02-26 2003-11-13 Bylund Adam David Systems and methods for remotely controlling medication infusion and analyte monitoring
US20030186446A1 (en) 2002-04-02 2003-10-02 Jerry Pugh Test strip containers and methods of using the same
US8702624B2 (en) 2006-09-29 2014-04-22 Sanofi-Aventis Deutschland Gmbh Analyte measurement device with a single shot actuator
US7343188B2 (en) * 2002-05-09 2008-03-11 Lifescan, Inc. Devices and methods for accessing and analyzing physiological fluid
CA2392980A1 (en) * 2002-07-11 2004-01-11 Lifescan, Inc. Electrochemical test strip having a plurality of reaction chambers and methods for using the same
US6780645B2 (en) 2002-08-21 2004-08-24 Lifescan, Inc. Diagnostic kit with a memory storing test strip calibration codes and related methods
CA2437249A1 (en) * 2002-08-27 2004-02-27 Bayer Healthcare, Llc Methods of determining glucose concentration in whole blood samples
US7291256B2 (en) * 2002-09-12 2007-11-06 Lifescan, Inc. Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays
US20050049522A1 (en) * 2002-10-30 2005-03-03 Allen John J Method of lancing skin for the extraction of blood
US8574895B2 (en) 2002-12-30 2013-11-05 Sanofi-Aventis Deutschland Gmbh Method and apparatus using optical techniques to measure analyte levels
JP4866232B2 (en) * 2003-01-20 2012-02-01 ユニバーサル バイオセンサーズ ピーティーワイ リミテッドUniversal Biosensors Pty Limited Electrochemical detection method and apparatus
US20050176133A1 (en) * 2003-02-21 2005-08-11 Matsushita Electric Industrial Co., Ltd. Measuring instrument for biosensor and measuring method using same
US20040193072A1 (en) * 2003-03-28 2004-09-30 Allen John J. Method of analyte measurement using integrated lance and strip
US7473264B2 (en) * 2003-03-28 2009-01-06 Lifescan, Inc. Integrated lance and strip for analyte measurement
US20040193202A1 (en) * 2003-03-28 2004-09-30 Allen John J. Integrated lance and strip for analyte measurement
EP1628567B1 (en) 2003-05-30 2010-08-04 Pelikan Technologies Inc. Method and apparatus for fluid injection
US7850621B2 (en) 2003-06-06 2010-12-14 Pelikan Technologies, Inc. Method and apparatus for body fluid sampling and analyte sensing
KR100554649B1 (en) * 2003-06-09 2006-02-24 주식회사 아이센스 Electrochemical biosensor
US7488601B2 (en) 2003-06-20 2009-02-10 Roche Diagnostic Operations, Inc. System and method for determining an abused sensor during analyte measurement
US7718439B2 (en) 2003-06-20 2010-05-18 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8206565B2 (en) 2003-06-20 2012-06-26 Roche Diagnostics Operation, Inc. System and method for coding information on a biosensor test strip
US7452457B2 (en) 2003-06-20 2008-11-18 Roche Diagnostics Operations, Inc. System and method for analyte measurement using dose sufficiency electrodes
KR100785670B1 (en) 2003-06-20 2007-12-14 에프. 호프만-라 로슈 아게 Method and reagent for producing narrow, homogenous reagent strips
US8071030B2 (en) 2003-06-20 2011-12-06 Roche Diagnostics Operations, Inc. Test strip with flared sample receiving chamber
US7645421B2 (en) 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8058077B2 (en) 2003-06-20 2011-11-15 Roche Diagnostics Operations, Inc. Method for coding information on a biosensor test strip
US8679853B2 (en) 2003-06-20 2014-03-25 Roche Diagnostics Operations, Inc. Biosensor with laser-sealed capillary space and method of making
US7645373B2 (en) 2003-06-20 2010-01-12 Roche Diagnostic Operations, Inc. System and method for coding information on a biosensor test strip
US7220034B2 (en) * 2003-07-11 2007-05-22 Rudolph Technologies, Inc. Fiber optic darkfield ring light
US20100185071A1 (en) * 2003-12-05 2010-07-22 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
US8010174B2 (en) 2003-08-22 2011-08-30 Dexcom, Inc. Systems and methods for replacing signal artifacts in a glucose sensor data stream
US7682833B2 (en) * 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
WO2005033659A3 (en) 2003-09-29 2007-01-18 Pelikan Technologies Inc Method and apparatus for an improved sample capture device
WO2005037095A1 (en) 2003-10-14 2005-04-28 Pelikan Technologies, Inc. Method and apparatus for a variable user interface
KR20060132434A (en) 2003-11-06 2006-12-21 라이프스캔, 인코포레이티드 Drug delivery pen with event notification means
KR101049330B1 (en) * 2003-12-04 2011-07-13 파나소닉 주식회사 How to measure the hematocrit, and the sensor and measuring device using it
EP1691192B1 (en) 2003-12-04 2015-07-01 Panasonic Healthcare Holdings Co., Ltd. Blood component measuring method
US8287453B2 (en) 2003-12-05 2012-10-16 Dexcom, Inc. Analyte sensor
US8423114B2 (en) 2006-10-04 2013-04-16 Dexcom, Inc. Dual electrode system for a continuous analyte sensor
EP2239567B1 (en) 2003-12-05 2015-09-02 DexCom, Inc. Calibration techniques for a continuous analyte sensor
EP1711791B1 (en) 2003-12-09 2014-10-15 DexCom, Inc. Signal processing for continuous analyte sensor
WO2005065414A3 (en) 2003-12-31 2005-12-29 Pelikan Technologies Inc Method and apparatus for improving fluidic flow and sample capture
JP2007523326A (en) 2004-02-06 2007-08-16 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC Species that may be oxidized as an internal standard for biosensors, and method of use
US20050187525A1 (en) * 2004-02-19 2005-08-25 Hilgers Michael E. Devices and methods for extracting bodily fluid
CA2557690A1 (en) * 2004-03-31 2005-10-20 George A. Mecklenburg Method and apparatus for implementing threshold based correction functions for biosensors
EP1742045B1 (en) 2004-04-19 2016-11-02 Panasonic Healthcare Holdings Co., Ltd. Method for measuring blood components and biosensor and measuring instrument for use therein
US7972861B2 (en) * 2004-05-14 2011-07-05 Bayer Healthcare Llc Methods for performing hematocrit adjustment in glucose assays and devices for same
RU2386960C2 (en) * 2004-05-14 2010-04-20 БАЙЕР ХЕЛТКЭР ЭлЭлСи Voltammetric system for analysing biological substances
EP1751546A2 (en) 2004-05-20 2007-02-14 Albatros Technologies GmbH & Co. KG Printable hydrogel for biosensors
DK1766400T3 (en) * 2004-06-03 2009-07-20 Meso Scale Technologies Llc A method to perform whole blood analyzes
US9775553B2 (en) 2004-06-03 2017-10-03 Sanofi-Aventis Deutschland Gmbh Method and apparatus for a fluid sampling device
EP1765194A4 (en) 2004-06-03 2010-09-29 Pelikan Technologies Inc Method and apparatus for a fluid sampling device
WO2006001797A1 (en) 2004-06-14 2006-01-05 Pelikan Technologies, Inc. Low pain penetrating
US7569126B2 (en) 2004-06-18 2009-08-04 Roche Diagnostics Operations, Inc. System and method for quality assurance of a biosensor test strip
US20050284757A1 (en) * 2004-06-29 2005-12-29 Allen John J Analyte measuring system which prevents the reuse of a test strip
US20050284773A1 (en) * 2004-06-29 2005-12-29 Allen John J Method of preventing reuse in an analyte measuring system
US20060000710A1 (en) 2004-06-30 2006-01-05 Klaus Peter Weidenhaupt Fluid handling methods
US7497827B2 (en) 2004-07-13 2009-03-03 Dexcom, Inc. Transcutaneous analyte sensor
CN102507695B (en) 2004-10-12 2015-12-02 拜尔健康护理有限责任公司 Determination of the concentration of the diffusion barrier layer
US8652831B2 (en) 2004-12-30 2014-02-18 Sanofi-Aventis Deutschland Gmbh Method and apparatus for analyte measurement test time
US7822454B1 (en) 2005-01-03 2010-10-26 Pelikan Technologies, Inc. Fluid sampling device with improved analyte detecting member configuration
GB0503836D0 (en) * 2005-02-24 2005-04-06 Axis Shield Asa Method
US7964089B2 (en) * 2005-04-15 2011-06-21 Agamatrix, Inc. Analyte determination method and analyte meter
US7547382B2 (en) * 2005-04-15 2009-06-16 Agamatrix, Inc. Determination of partial fill in electrochemical strips
US8192599B2 (en) * 2005-05-25 2012-06-05 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8323464B2 (en) * 2005-05-25 2012-12-04 Universal Biosensors Pty Ltd Method and apparatus for electrochemical analysis
US8016154B2 (en) * 2005-05-25 2011-09-13 Lifescan, Inc. Sensor dispenser device and method of use
KR101321296B1 (en) 2005-07-20 2013-10-28 바이엘 헬스케어 엘엘씨 Gated amperometry temperature determination
US7749371B2 (en) * 2005-09-30 2010-07-06 Lifescan, Inc. Method and apparatus for rapid electrochemical analysis
KR101477948B1 (en) 2005-09-30 2014-12-30 바이엘 헬스케어 엘엘씨 Gated voltammetry analysis duration determination
US7955484B2 (en) * 2005-12-14 2011-06-07 Nova Biomedical Corporation Glucose biosensor and method
US8163162B2 (en) * 2006-03-31 2012-04-24 Lifescan, Inc. Methods and apparatus for analyzing a sample in the presence of interferents
US8529751B2 (en) * 2006-03-31 2013-09-10 Lifescan, Inc. Systems and methods for discriminating control solution from a physiological sample
US20070235346A1 (en) * 2006-04-11 2007-10-11 Popovich Natasha D System and methods for providing corrected analyte concentration measurements
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
US20080083618A1 (en) 2006-09-05 2008-04-10 Neel Gary T System and Methods for Determining an Analyte Concentration Incorporating a Hematocrit Correction
CA2664186A1 (en) * 2006-09-22 2008-03-27 Bayer Healthcare Llc Biosensor system having enhanced stability and hematocrit performance
US8364231B2 (en) 2006-10-04 2013-01-29 Dexcom, Inc. Analyte sensor
US9046480B2 (en) 2006-10-05 2015-06-02 Lifescan Scotland Limited Method for determining hematocrit corrected analyte concentrations
EP2437056B1 (en) 2006-10-05 2013-11-20 Lifescan Scotland Ltd Methods for determining the presence of a sufficient quantity of fluid sample on a test strip
US20100276303A1 (en) * 2006-10-19 2010-11-04 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
US8691072B2 (en) 2006-10-19 2014-04-08 Panasonic Corporation Method for measuring hematocrit value of blood sample, method for measuring concentration of analyte in blood sample, sensor chip and sensor unit
WO2008051742A3 (en) 2006-10-24 2008-06-19 Bayer Healthcare Llc Transient decay amperometry
GB0705495D0 (en) * 2007-03-22 2007-05-02 Quotient Diagnostics Ltd Whole blood assay
US20090026094A1 (en) * 2007-05-11 2009-01-29 Home Diagnostics, Inc. Two-pulse systems and methods for determining analyte concentration
US8080153B2 (en) 2007-05-31 2011-12-20 Abbott Diabetes Care Inc. Analyte determination methods and devices
GB0711780D0 (en) * 2007-06-18 2007-07-25 Oxford Biosensors Ltd Electrochemical data rejection methodology
EP2192402B1 (en) * 2007-09-18 2013-11-27 Ultizyme International Ltd. Enzyme electrode
US8778168B2 (en) 2007-09-28 2014-07-15 Lifescan, Inc. Systems and methods of discriminating control solution from a physiological sample
US8001825B2 (en) * 2007-11-30 2011-08-23 Lifescan, Inc. Auto-calibrating metering system and method of use
JP5812603B2 (en) * 2007-12-10 2015-11-17 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC Gradient-based correction
RU2518310C2 (en) * 2007-12-10 2014-06-10 БАЙЕР ХЕЛТКЭА ЭлЭлСи Reagents and methods for detecting analytes
RU2491549C2 (en) 2007-12-10 2013-08-27 БАЙЕР ХЕЛТКЭА ЭлЭлСи Amperometry with strobing and fast reading
JP2011506967A (en) * 2007-12-10 2011-03-03 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC Method and system for generating a reagent background current drops
US8603768B2 (en) 2008-01-17 2013-12-10 Lifescan, Inc. System and method for measuring an analyte in a sample
USD612279S1 (en) 2008-01-18 2010-03-23 Lifescan Scotland Limited User interface in an analyte meter
KR100967621B1 (en) 2008-01-22 2010-07-05 전남대학교산학협력단 The method for reducing measurement error using kinetic changing information and the apparatus thereof
USD611853S1 (en) 2008-03-21 2010-03-16 Lifescan Scotland Limited Analyte test meter
USD615431S1 (en) 2008-03-21 2010-05-11 Lifescan Scotland Limited Analyte test meter
CA2659142C (en) 2008-03-21 2017-10-03 Lifescan Scotland Limited Analyte testing method and system
USD612275S1 (en) 2008-03-21 2010-03-23 Lifescan Scotland, Ltd. Analyte test meter
US8008037B2 (en) 2008-03-27 2011-08-30 Roche Diagnostics Operations, Inc. Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline
WO2009126900A1 (en) 2008-04-11 2009-10-15 Pelikan Technologies, Inc. Method and apparatus for analyte detecting device
US8551320B2 (en) 2008-06-09 2013-10-08 Lifescan, Inc. System and method for measuring an analyte in a sample
USD611151S1 (en) 2008-06-10 2010-03-02 Lifescan Scotland, Ltd. Test meter
CN102089650B (en) 2008-07-10 2014-01-29 拜尔健康护理有限责任公司 Systems and methods including amperometric and voltammetric duty cycles
USD611489S1 (en) 2008-07-25 2010-03-09 Lifescan, Inc. User interface display for a glucose meter
USD611372S1 (en) 2008-09-19 2010-03-09 Lifescan Scotland Limited Analyte test meter
KR20110079701A (en) * 2008-09-30 2011-07-07 멘나이 메디컬 테크놀로지즈 리미티드 Sample measurement system
JP5738770B2 (en) 2008-12-08 2015-06-24 バイエル・ヘルスケア・エルエルシーBayer HealthCareLLC Biosensor system with signal conditioning
US9375169B2 (en) 2009-01-30 2016-06-28 Sanofi-Aventis Deutschland Gmbh Cam drive for managing disposable penetrating member actions with a single motor and motor and control system
CA2766865A1 (en) * 2009-06-30 2011-01-06 Lifescan, Inc. Analyte testing method and system
WO2011008520A3 (en) 2009-06-30 2011-04-07 Lifescan, Inc. Analyte testing methods and device for calculating basal insulin therapy
RU2552312C2 (en) * 2009-06-30 2015-06-10 Лайфскэн Скотлэнд Лимитед Systems and methods for diabetes control
RU2606769C2 (en) * 2009-09-04 2017-01-10 Лайфскэн Скотлэнд Лимитед Glucose measurement method and system
US8545693B2 (en) * 2009-09-29 2013-10-01 Lifescan Scotland Limited Analyte measurment method and system
CN102639058B (en) 2009-09-29 2015-11-25 生命扫描苏格兰有限公司 Analyte testing methods and apparatus for the management of diabetes
US8760178B2 (en) * 2009-09-30 2014-06-24 Arkray, Inc. Method for measuring target component in erythrocyte-containing specimen
JP5350960B2 (en) 2009-09-30 2013-11-27 アークレイ株式会社 Method of measuring the target component in the erythrocyte-containing specimen
CA2784351C (en) 2009-12-18 2013-10-08 Abbott Point Of Care Inc. Integrated hinged cartridge housings for sample analysis
US8101065B2 (en) * 2009-12-30 2012-01-24 Lifescan, Inc. Systems, devices, and methods for improving accuracy of biosensors using fill time
US8877034B2 (en) * 2009-12-30 2014-11-04 Lifescan, Inc. Systems, devices, and methods for measuring whole blood hematocrit based on initial fill velocity
US8844725B2 (en) * 2010-01-20 2014-09-30 Roche Diagnostics Operations, Inc. Test strip container with strip retainer and methods of manufacturing and utilization thereof
US8773106B2 (en) 2010-02-25 2014-07-08 Lifescan Scotland Limited Capacitance detection in electrochemical assay with improved sampling time offset
US8742773B2 (en) 2010-02-25 2014-06-03 Lifescan Scotland Limited Capacitance detection in electrochemical assay with improved response
EP2539711B1 (en) 2010-02-25 2014-01-22 Lifescan Scotland Limited Capacitance detection in electrochemical assay
CA2790910A1 (en) 2010-02-25 2011-09-01 Lifescan Scotland Limited Analyte testing method and system with high and low blood glucose trends notification
US20110208435A1 (en) 2010-02-25 2011-08-25 Lifescan Scotland Ltd. Capacitance detection in electrochemical assays
US20110205065A1 (en) 2010-02-25 2011-08-25 Lifescan Scotland Ltd. Analyte testing method and system with safety warning for insulin dosing
KR20130016311A (en) * 2010-03-22 2013-02-14 바이엘 헬쓰케어, 엘엘씨 Residual compensation for a biosensor
GB201005359D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
GB201005357D0 (en) 2010-03-30 2010-05-12 Menai Medical Technologies Ltd Sampling plate
US8965476B2 (en) 2010-04-16 2015-02-24 Sanofi-Aventis Deutschland Gmbh Tissue penetration device
US8394343B2 (en) 2010-04-27 2013-03-12 Roche Diagnostics Operations, Inc. Integrated test strip container with retaining insert
US20110278321A1 (en) 2010-05-11 2011-11-17 Roche Diagnostics Operations, Inc. Hermetically sealed test strip container
US9795747B2 (en) 2010-06-02 2017-10-24 Sanofi-Aventis Deutschland Gmbh Methods and apparatus for lancet actuation
WO2011156152A1 (en) 2010-06-07 2011-12-15 Bayer Healthcare Llc Slope-based compensation including secondary output signals
WO2012001365A8 (en) 2010-06-30 2013-01-31 Lifescan Scotland Limited Methods to ensure statistical power for average pre and post - prandial glucose difference messaging
US8932445B2 (en) 2010-09-30 2015-01-13 Cilag Gmbh International Systems and methods for improved stability of electrochemical sensors
US8617370B2 (en) 2010-09-30 2013-12-31 Cilag Gmbh International Systems and methods of discriminating between a control sample and a test fluid using capacitance
US8349612B2 (en) 2010-11-15 2013-01-08 Roche Diagnostics Operations, Inc. Guided structured testing kit
JP6082396B2 (en) 2011-09-21 2017-02-15 バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC Bio-sensor with the error compensation
KR101333225B1 (en) * 2011-10-27 2013-11-26 광주과학기술원 Method and apparatus for measuring hematocrit
KR101367262B1 (en) 2011-11-11 2014-02-26 주식회사 아이센스 Blood Glucose Sensor and sensing error detecting method using thereof
US9081001B2 (en) 2012-05-15 2015-07-14 Wellstat Diagnostics, Llc Diagnostic systems and instruments
US9213043B2 (en) 2012-05-15 2015-12-15 Wellstat Diagnostics, Llc Clinical diagnostic system including instrument and cartridge
US9625465B2 (en) 2012-05-15 2017-04-18 Defined Diagnostics, Llc Clinical diagnostic systems
US9903830B2 (en) 2011-12-29 2018-02-27 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip based on sensed physical characteristic(s) of the sample containing the analyte
WO2013144617A1 (en) 2012-03-30 2013-10-03 Lifescan Scotland Limited Battery status detection and storage method and system in medical monitoring
KR101466222B1 (en) 2012-06-01 2014-12-01 주식회사 아이센스 Electrochemical biosensor with improved accuracy
US9080196B2 (en) 2012-09-28 2015-07-14 Cilag Gmbh International System and method for determining hematocrit insensitive glucose concentration
US9005426B2 (en) 2012-09-28 2015-04-14 Cilag Gmbh International System and method for determining hematocrit insensitive glucose concentration
US9005901B2 (en) * 2013-03-15 2015-04-14 Abbott Laboratories Assay with internal calibration
GB2515299B (en) * 2013-06-18 2015-12-30 Suresensors Ltd Methods and apparatus for determining analyte in a sample
US9435762B2 (en) 2013-06-27 2016-09-06 Lifescan Scotland Limited Fill error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9835578B2 (en) 2013-06-27 2017-12-05 Lifescan Scotland Limited Temperature compensation for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9435764B2 (en) 2013-06-27 2016-09-06 Lifescan Scotland Limited Transient signal error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
US9459231B2 (en) 2013-08-29 2016-10-04 Lifescan Scotland Limited Method and system to determine erroneous measurement signals during a test measurement sequence
US9243276B2 (en) 2013-08-29 2016-01-26 Lifescan Scotland Limited Method and system to determine hematocrit-insensitive glucose values in a fluid sample
US9828621B2 (en) 2013-09-10 2017-11-28 Lifescan Scotland Limited Anomalous signal error trap for an analyte measurement determined from a specified sampling time derived from a sensed physical characteristic of the sample containing the analyte
WO2015061598A1 (en) 2013-10-24 2015-04-30 Quidel Corporation Systems and methods for whole blood assays
DE102013227125B4 (en) 2013-12-23 2016-04-07 Senslab-Gesellschaft Zur Entwicklung Und Herstellung Bioelektrochemischer Sensoren Mbh A method for determining a measurement signal hämatokritabhängigen in the determination of an analyte from whole blood using enzymatically-voltammetric Disposable sensors
RU2548778C1 (en) * 2014-02-10 2015-04-20 Виталий Юрьевич Мишланов Diagnostic technique for blood serum glucose, total protein and electrolytes by multi-frequency impedance analysis
DE202014100630U1 (en) 2014-02-13 2014-02-18 Sanofi-Aventis Deutschland Gmbh gauge
KR101666978B1 (en) 2014-09-17 2016-10-24 주식회사 아이센스 Apparatus and Method for measuring concentration of Whole Blood Samples Using the same
US20160091451A1 (en) 2014-09-25 2016-03-31 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip to determine analyte measurement time based on measured temperature, physical characteristic and estimated analyte value
US20160091450A1 (en) 2014-09-25 2016-03-31 Lifescan Scotland Limited Accurate analyte measurements for electrochemical test strip to determine analyte measurement time based on measured temperature, physical characteristic and estimated analyte value and their temperature compensated values
GB201419113D0 (en) 2014-10-27 2014-12-10 Accunostics Ltd Method for determining diffusion
WO2016092317A1 (en) * 2014-12-11 2016-06-16 Inside Biometrics Limited Method of determining parameters of a test fluid
US9903832B2 (en) 2015-04-28 2018-02-27 Industrial Technology Research Institute Methods for measuring analyte concentration
GB201511299D0 (en) * 2015-06-26 2015-08-12 Inside Biometrics Ltd Test device and method of using a test device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089320A (en) * 1989-01-09 1992-02-18 James River Ii, Inc. Resealable packaging material
US5264103A (en) 1991-10-18 1993-11-23 Matsushita Electric Industrial Co., Ltd. Biosensor and a method for measuring a concentration of a substrate in a sample
US5353351A (en) * 1992-06-09 1994-10-04 At&T Bell Laboratories Secure teleconferencing
US5437999A (en) * 1994-02-22 1995-08-01 Boehringer Mannheim Corporation Electrochemical sensor
US5628890A (en) * 1995-09-27 1997-05-13 Medisense, Inc. Electrochemical sensor
US5633169A (en) * 1995-10-27 1997-05-27 Nova Biomedical Corporation Measurement of carbon dioxide in blood
CA2236850C (en) 1995-11-16 2004-06-01 Alastair Mcindoe Hodges Electrochemical cell
CA2310021C (en) 1997-12-22 2005-02-15 Roche Diagnostics Corporation An apparatus and method for determining the concentration of a component in a fluid
JP3848993B2 (en) 1998-01-06 2006-11-22 アークレイ株式会社 Component of the measuring method and the measuring apparatus in the presence of a coexisting substance
US6576117B1 (en) * 1998-05-20 2003-06-10 Arkray Method and apparatus for electrochemical measurement using statistical technique
US6287451B1 (en) * 1999-06-02 2001-09-11 Handani Winarta Disposable sensor and method of making
US6475372B1 (en) * 2000-02-02 2002-11-05 Lifescan, Inc. Electrochemical methods and devices for use in the determination of hematocrit corrected analyte concentrations
US20020092612A1 (en) * 2000-03-28 2002-07-18 Davies Oliver William Hardwicke Rapid response glucose sensor

Also Published As

Publication number Publication date Type
US6890421B2 (en) 2005-05-10 grant
CN1193228C (en) 2005-03-16 grant
DE60116056T2 (en) 2006-08-10 grant
WO2001057510A2 (en) 2001-08-09 application
CN1394280A (en) 2003-01-29 application
US20020125145A1 (en) 2002-09-12 application
RU2002116217A (en) 2004-01-20 application
US20050176153A1 (en) 2005-08-11 application
ES2254368T3 (en) 2006-06-16 grant
EP1645876A3 (en) 2008-03-05 application
JP2003521708A (en) 2003-07-15 application
EP1252514B1 (en) 2005-12-21 grant
RU2005123794A (en) 2007-02-10 application
DK1252514T3 (en) 2006-05-01 grant
EP1645876A2 (en) 2006-04-12 application
US6475372B1 (en) 2002-11-05 grant
DE60116056D1 (en) 2006-01-26 grant
RU2262890C2 (en) 2005-10-27 grant
WO2001057510A3 (en) 2002-02-21 application
EP1252514A2 (en) 2002-10-30 application

Similar Documents

Publication Publication Date Title
US6287451B1 (en) Disposable sensor and method of making
US6749740B2 (en) Small volume in vitro analyte sensor and methods
US7058437B2 (en) Methods of determining concentration of glucose
USRE36268E (en) Method and apparatus for amperometric diagnostic analysis
US6153069A (en) Apparatus for amperometric Diagnostic analysis
US5108564A (en) Method and apparatus for amperometric diagnostic analysis
US6814843B1 (en) Biosensor
US6284125B1 (en) Electrochemical cell
US6558528B1 (en) Electrochemical test strip cards that include an integral dessicant
US6413410B1 (en) Electrochemical cell
US7276147B2 (en) Method for determining the concentration of an analyte in a liquid sample using small volume samples and fast test times
US6872298B2 (en) Determination of sample volume adequacy in biosensor devices
US7022217B2 (en) Electrochemical method for measuring chemical reaction rates
US7225535B2 (en) Method of manufacturing electrochemical sensors
US7276146B2 (en) Electrodes, methods, apparatuses comprising micro-electrode arrays
US6911621B2 (en) Biosensor
US20100267161A1 (en) Multi-Region and Potential Test Sensors, Methods, and Systems
US6863800B2 (en) Electrochemical biosensor strip for analysis of liquid samples
US20080179197A1 (en) Gated Voltammetry
US20070235346A1 (en) System and methods for providing corrected analyte concentration measurements
US20030036202A1 (en) Methods and devices for use in analyte concentration determination assays
US20080105568A1 (en) Voltammetric Systems For Assaying Biological Analytes
EP0406304B1 (en) Method and apparatus for amperometric diagnostic analysis
US6852212B2 (en) Method and apparatus for automatic analysis
US7291256B2 (en) Mediator stabilized reagent compositions and methods for their use in electrochemical analyte detection assays

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead